“It seems that the sands of time are slowly running out on Eli Lilly’s BACE program for treating Alzheimer’s disease. This week during its third quarter conference call, David Ricks, Eli Lilly’s Chief Executive Officer, slid in the fact that the company has scrapped a Phase II clinical trial for N3pG, a humanized IgG1 monoclonal antibody, plus BACE in the treatment of Alzheimer’s. Ricks did note that Eli Lilly was still studying N3pG as a monotherapy.”
Read the Full Story at www.biospace.com
Eli Lilly Quietly Scraps a BACE Program for Alzheimer’s
More from Current EventMore posts in Current Event »
- Failure of once-promising Alzheimer’s drug reinforces doubts about amyloid beta | Med City News
- Former NFL Wife on Her Husband’s Battle with CTE
- Capito, Collins introduce bill to increase awareness of Alzheimer’s services | Ripon Advance
- ‘Young Blood’ Researchers Are Still in the Pursuit to Stall Aging, Slow Alzheimer’s | Being Patient
- ‘It is not alarmist to say that the people of Florida are being slowly poisoned by the water’ | Opinion | Miami Herald